Pelthos Expands ZELSUVMI Coverage to 127 Million Lives
Event summary
- Pelthos secures formulary coverage with a major PBM, adding 24 million covered lives for ZELSUVMI.
- Regional health plan expands ZELSUVMI access to 3 million additional lives.
- Total commercial coverage for ZELSUVMI now reaches 127 million lives (69% of commercially insured).
- ZELSUVMI maintains strong Medicaid coverage across 70 million lives (100% of covered lives).
The big picture
Pelthos' expanded formulary coverage for ZELSUVMI underscores its strategic focus on maximizing patient access for a condition with limited treatment options. The move aligns with broader industry trends toward value-based care and payer-driven market access, particularly for dermatological therapies. With 127 million commercially insured lives now covered, Pelthos is positioning ZELSUVMI as a cornerstone in its portfolio of cutaneous infectious disease treatments.
What we're watching
- Market Penetration
- How Pelthos will leverage this expanded coverage to drive prescription uptake and revenue growth.
- Competitive Dynamics
- Whether Pelthos can sustain market share against potential future entrants in the molluscum contagiosum space.
- Regulatory Stability
- The pace at which Pelthos can maintain or expand ZELSUVMI's regulatory approvals and formulary status.